The clinical study to assess the efficacy, safety and pharmacokinetics of NS-304 in patients with pulmonary arterial hypertension (PAH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals; Nippon Shinyaku
- 18 Apr 2017 Primary endpoint (Change from baseline of pulmonary vascular resistance ) has been met,according to the results published in the Circulation Journal.
- 18 Apr 2017 Results published in the Circulation Journal
- 12 Jan 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.